Regenerative Medicine and Stem Cell Therapy for the Eye (eBook)
X, 212 Seiten
Springer International Publishing (Verlag)
978-3-319-98080-5 (ISBN)
- Skillfully reviews cutting-edge advances in stem cell biology as applied to regenerative medicine and ocular disease
- Provides expert viewpoints on key hurdles and challenges to successful implementation of stem cell-derived therapies in the clinical domain
- Offers a multi-disciplinary, broad understanding of cell-based therapies for ocular diseases by incorporating perspectives from biomedical scientists, physicians, and engineers
- Examines the connection between cell therapy and gene editing, in particular relation to ocular disease
Brian Ballios, M.D., Ph.D., Senior Research Associate and Resident Physician in the Department of Ophthalmology and Vision Sciences, University of Toronto, received his B.Sc.Eng. in Engineering Chemistry from Queen's University in 2007. He then completed a combined MD/PhD Program at the University of Toronto in 2015. During his graduate work, he developed new approaches to the transplantation of stem cells and their progeny for the treatment of retinal degeneration. His interests lie at the intersection of retinal neurobiology and applied science, as related to stem cell biology and bioengineering. He developed the first injectable biomaterial-based delivery system for stem cell transplantation in the retina. In 2016, he joined the Department of Ophthalmology and Vision Sciences as a Senior Research Associate, while also completing an ophthalmology residency.
Michael Young, Ph.D., Associate Scientist at the Schepens Eye Research Institute, received his BS degree in behavioral neuroscience from the University of Pittsburgh in 1989. He then received his PhD in anatomy/neuroscience from the University of Cambridge in 1995. A postdoctoral fellowship at the Institute of Ophthalmology, University College, London in 1995 was followed by a two-year postdoctoral fellowship at the Massachusetts Institute of Technology, Department of Brain and Cognitive Sciences. In 1998, Young joined the Schepens Eye Research Institute as an Investigator. He was elected the Director of the Minda deGunzburg Center for Ocular Regeneration. In 2008, he was promoted to Associate Professor in the Department of Ophthalmology, Harvard Medical School. He is now also Co-director of the Ocular Regenerative Medicine Institute at MEE/HMS.
Brian Ballios, M.D., Ph.D., Senior Research Associate and Resident Physician in the Department of Ophthalmology and Vision Sciences, University of Toronto, received his B.Sc.Eng. in Engineering Chemistry from Queen’s University in 2007. He then completed a combined MD/PhD Program at the University of Toronto in 2015. During his graduate work, he developed new approaches to the transplantation of stem cells and their progeny for the treatment of retinal degeneration. His interests lie at the intersection of retinal neurobiology and applied science, as related to stem cell biology and bioengineering. He developed the first injectable biomaterial-based delivery system for stem cell transplantation in the retina. In 2016, he joined the Department of Ophthalmology and Vision Sciences as a Senior Research Associate, while also completing an ophthalmology residency.Michael Young, Ph.D., Associate Scientist at the Schepens Eye Research Institute, received his BS degree in behavioral neuroscience from the University of Pittsburgh in 1989. He then received his PhD in anatomy/neuroscience from the University of Cambridge in 1995. A postdoctoral fellowship at the Institute of Ophthalmology, University College, London in 1995 was followed by a two-year postdoctoral fellowship at the Massachusetts Institute of Technology, Department of Brain and Cognitive Sciences. In 1998, Young joined the Schepens Eye Research Institute as an Investigator. He was elected the Director of the Minda deGunzburg Center for Ocular Regeneration. In 2008, he was promoted to Associate Professor in the Department of Ophthalmology, Harvard Medical School. He is now also Co-director of the Ocular Regenerative Medicine Institute at MEE/HMS.
1. Photoreceptor cell replacement therapy from stem cells2. Human Pluripotent Stem Cells as In Vitro Models for Retinal Development and Disease3. Clinical Applications of Limbal Stem Cells for Regenerative Medicine4. Bioengineered and Regenerative Medicine Strategies for Retina Repair5. Stem Cell Therapy and Regenerative Medicine in the Cornea6. Overview of Cells and Animal Models use for Retinal Stem Cell Research7. Limbal stem cells and the treatment of limbal stem cell deficiency8. Retinal ganglion cell replacement – A bridge to the brainIndex
Erscheint lt. Verlag | 18.2.2019 |
---|---|
Reihe/Serie | Fundamental Biomedical Technologies | Fundamental Biomedical Technologies |
Zusatzinfo | X, 212 p. 21 illus., 19 illus. in color. |
Verlagsort | Cham |
Sprache | englisch |
Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete ► Augenheilkunde |
Naturwissenschaften ► Biologie ► Genetik / Molekularbiologie | |
Naturwissenschaften ► Biologie ► Mikrobiologie / Immunologie | |
Schlagworte | Embryonic Stem Cells • induced-pluripotent stem cells • Limbal stem cells • ocular surface stem cell transplantation • photoreceptors transplantation • retinal pigment epithelium transplantation • retinal regeneration • retinal stem cells |
ISBN-10 | 3-319-98080-7 / 3319980807 |
ISBN-13 | 978-3-319-98080-5 / 9783319980805 |
Haben Sie eine Frage zum Produkt? |
Größe: 5,0 MB
DRM: Digitales Wasserzeichen
Dieses eBook enthält ein digitales Wasserzeichen und ist damit für Sie personalisiert. Bei einer missbräuchlichen Weitergabe des eBooks an Dritte ist eine Rückverfolgung an die Quelle möglich.
Dateiformat: PDF (Portable Document Format)
Mit einem festen Seitenlayout eignet sich die PDF besonders für Fachbücher mit Spalten, Tabellen und Abbildungen. Eine PDF kann auf fast allen Geräten angezeigt werden, ist aber für kleine Displays (Smartphone, eReader) nur eingeschränkt geeignet.
Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen dafür einen PDF-Viewer - z.B. den Adobe Reader oder Adobe Digital Editions.
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen dafür einen PDF-Viewer - z.B. die kostenlose Adobe Digital Editions-App.
Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.
aus dem Bereich